Found: 8
Select item for more details and to access through your institution.
Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 2, p. 560, doi. 10.3390/ijms22020560
- By:
- Publication type:
- Article
The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 1, p. 236, doi. 10.1016/j.molonc.2014.08.005
- By:
- Publication type:
- Article
The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
- Published in:
- Glia, 2012, v. 60, n. 11, p. 1721, doi. 10.1002/glia.22391
- By:
- Publication type:
- Article
Altered Adhesive Structures and Their Relation to RhoGTPase Activation in Merlin-Deficient Schwannoma.
- Published in:
- Brain Pathology, 2009, v. 19, n. 1, p. 27, doi. 10.1111/j.1750-3639.2008.00165.x
- By:
- Publication type:
- Article
Expression of c- Jun and Sox-2 in human schwannomas and traumatic neuromas.
- Published in:
- Histopathology, 2013, v. 62, n. 4, p. 651, doi. 10.1111/his.12062
- By:
- Publication type:
- Article
Investigating the role of TAM family receptors in Merlin deficient tumours.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. v358, doi. 10.1093/neuonc/noy130.068
- By:
- Publication type:
- Article
Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
- Published in:
- Neuro-Oncology, 2011, v. 13, n. 7, p. 759, doi. 10.1093/neuonc/nor056
- By:
- Publication type:
- Article
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma†.
- Published in:
- Neuro-Oncology, 2010, v. 12, n. 8, p. 834, doi. 10.1093/neuonc/noq012
- By:
- Publication type:
- Article